journal article·2013-03-01

The protein corona effect for targeted drug delivery

Giulio Caracciolo

Publisher page

Abstract

At present, ligand binding to nanoparticle surface is the most widespread strategy for targeting specific tissues by a receptor-mediated mechanism. However, the nanoparticles are immediately covered by a protein-rich layer when administrated in vivo, the so-called “protein corona”, with the immediate consequence that the ligand-receptor recognition may be obscured. It is not the nanoparticle-bulk composition or surface functionalization but rather the identity, arrangement and residence time of the proteins of the corona that determine the nanoparticle bioidentity, and this is an emerging concept available for use to target specific cell types in a controlled manner. An in-depth understanding of the relationship between surface properties of nanoparticles and composition of the “protein corona” is a fundamental step toward the design of nanoparticles that, once in the blood, become covered by specific proteins able to deliver them at the right site of action and promote efficient cell internalization. This “protein corona effect” is a formidable challenge that could lead to a complete renewal of the current strategies of targeted drug delivery.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Polymer Surface Interaction Studies · Iron oxide chemistry and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Molecular Medicine, ‘‘Sapienza’’ University of Rome, Rome, Italy

References (33)

Show source-provided references
1. Devalapally H. · Journal of Pharmacobio-Dynamics · 2007 · 96 · 2547
2. 10.1002/wnan.14310.1002/wnan.143 ↗
3. Yan Y. · Action (National Fund for Research into Crippling Diseases) · 2012 · 6 · 3663
4. 10.1146/annurev-med-040210-16254410.1146/annurev-med-040210-162544 ↗
5. Khanna V. K. · ISRN Pharmacology · 2012 · 2012 · 1
6. 10.1016/S0168-3659(99)00248-510.1016/S0168-3659(99)00248-5 ↗
7. Matsumura Y. · Cancer Research · 1986 · 46 · 6387
8. 10.1016/j.addr.2010.05.00110.1016/j.addr.2010.05.001 ↗
9. 10.1073/pnas.091414010710.1073/pnas.0914140107 ↗
10. 10.3109/09687688.2010.52120010.3109/09687688.2010.521200 ↗
11. 10.2174/13816120978700287010.2174/138161209787002870 ↗
12. Chattopadhyay N. · Molecular Pharmaceutics · 2012 · 9 · 216810.1021/mp300016p ↗
13. 10.1016/j.jconrel.2005.04.00310.1016/j.jconrel.2005.04.003 ↗
14. Dams E. T. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 292 · 107110.1016/S0022-3565(24)35391-1 ↗
15. 10.1002/anie.20070046510.1002/anie.200700465 ↗
16. 10.1073/pnas.080513510510.1073/pnas.0805135105 ↗
17. 10.1016/S1748-0132(08)70014-810.1016/S1748-0132(08)70014-8 ↗
18. 10.1021/ja107583h10.1021/ja107583h ↗
19. 10.1038/nnano.2010.26710.1038/nnano.2010.267 ↗
20. 10.1016/j.jconrel.2012.04.00910.1016/j.jconrel.2012.04.009 ↗
21. 10.1021/ja208433810.1021/ja2084338 ↗
22. 10.1016/j.ab.2011.08.00310.1016/j.ab.2011.08.003 ↗
23. Capriotti A. L. · Journal of Prosthodontics · 2012 · 75 · 1924
24. Fleischer C. C. · Journal of Pharmacobio-Dynamics B · 2012 · 116 · 8901
25. 10.1016/j.biomaterials.2011.12.01610.1016/j.biomaterials.2011.12.016 ↗
26. Caracciolo G. · Technical Proceedings of the 2012 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech · 2012 · 354
27. 10.1016/j.taap.2005.07.01710.1016/j.taap.2005.07.017 ↗
28. 10.1038/nnano.2010.25010.1038/nnano.2010.250 ↗
29. 10.1021/ja300537u10.1021/ja300537u ↗
30. 10.1016/j.biomaterials.2010.09.04910.1016/j.biomaterials.2010.09.049 ↗
31. Lundqvist M. · Action (National Fund for Research into Crippling Diseases) · 2011 · 5 · 7503
32. 10.1371/journal.pone.004068510.1371/journal.pone.0040685 ↗
33. Sandin P. · Action (National Fund for Research into Crippling Diseases) · 2012 · 6 · 1513